|Bid||0.6850 x 800|
|Ask||0.6900 x 4000|
|Day's Range||0.6700 - 0.7200|
|52 Week Range||0.6550 - 4.2000|
|Beta (5Y Monthly)||2.99|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2023 - May 15, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.06|
Aurora Cannabis Inc. ("Aurora" or the "Company") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, today announced that it has repurchased an aggregate of approximately $46.6 million (US$34.3 million) principal amount of its convertible senior notes ("Notes") at a total cost, including accrued interest, of $45.6 million (US$33.6 million) in cash, saving $2.6 million in annualized interest payments. Following completion of this repurchase, Aurora will have approximatel
Restructuring and changes in strategy are moves that businesses often deploy when they're facing challenges and headwinds. While Aurora Cannabis (NASDAQ: ACB) has been slashing costs and changing its operations in recent years, the company isn't out of the woods by any stretch. Among the biggest moves that Aurora has made in recent years has been to shift its business more toward medical marijuana.
Aurora Cannabis (NASDAQ: ACB) is one of the few Canadian cannabis retailers that is still seeing revenue growth, despite price compression and illegal sales negatively impacting the industry. The company is still losing money, but it appears to be edging its way toward profitability. Aurora's path to success includes branching out to international markets while focusing more on medical marijuana sales at home.